A Phase 3 interventional study of SPM 962 in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Per ClinicalTrials.gov, last updated 2014-03-19.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 9th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2009, is one of 20 in phase 3, and was the 25th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 2 started in 2009.
This study's enrollment of 321 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 3, and was the 7th registered.
Otsuka Holdings Co., Ltd.’s Parkinson Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 12 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SPM 962 transdermal patch
Drug: SPM 962
SPM 962 transdermal patch once a daily up to 36.0 mg/day
Also known as: rotigotine
Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters
The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed.
Time frame: Up to 55 weeks after dosing
Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state). UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, Up to 54 weeks after dosing
UPDRS Part 2 Sum Score (Average of on State and Off State)
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state). UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
Absolute Time Spent "Off"
Mean number of hours in "off state" during a 24-hour period.
Time frame: Baseline, up to 54 weeks after dosing
UPDRS Part 1 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 1 sum score. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
UPDRS Part 2 Sum Score (On State)
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
UPDRS Part 2 Sum Score (Off State)
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
UPDRS Part 4 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 4 sum score. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score
Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score. A decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
The Modified Hoehn & Yahr Severity of Illness
Change (LOCF) from baseline in the Modified Hoehn \& Yahr Severity of Illness. The Modified Hoehn \& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided. The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
Each Item of UPDRS Part 1
The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
Each Item of UPDRS Part 2 (on State)
The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
Each Item of UPDRS Part 2 (Off State)
The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
Each Item of UPDRS Part 2 (Average of on State and Off State)
The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State)
Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state). A decrease in the scores means improvement.
Time frame: Baseline, up to 54 weeks after dosing
Each Item of UPDRS Part 3 (on State)
The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
Each Item of UPDRS Part 4
The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown.
Time frame: Baseline, up to 54 weeks after dosing.
| Milestone | SPM 962 |
|---|---|
| Started | 321 |
| Completed | 256 |
| Not completed | 65 |
| Withdrew: Adverse event | 42 |
| Withdrew: Lack of efficacy | 7 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Discontinuation criteria | 1 |
| Withdrew: Physician decision | 2 |
The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed.
| participants | SPM 962 |
|---|---|
| Any AEs | 311 |
| Treatment-related AEs | 269 |
| SAEs | 34 |
| Treatment-related SAEs | 6 |
| Severe AEs | 16 |
| Discontinuation due to AEs | 47 |
| Death | 1 |
| AEs of special interest 1 | 7 |
| AEs of special interest 2 | 4 |
| AEs of special interest 3 | 54 |
| Valvular disease of the heart | 0 |
| Sitting systolic blood pressure, ≤ 100 mmHg | 9 |
| QTcB ≥ 500 ms | 5 |
| QTcF ≥ 500 ms | 2 |
| Application site reaction ≥ +++ | 14 |
| Weight decrease reported as AE | 8 |
Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state). UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -8.3 ± 7.1 |
| Week 24 | -8.0 ± 7.6 |
| Week 52 | -7.5 ± 8.6 |
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state). UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -2.6 ± 3.0 |
| Week 24 | -2.5 ± 3.4 |
| Week 52 | -1.9 ± 4.0 |
Mean number of hours in "off state" during a 24-hour period.
| Hours | SPM 962 |
|---|---|
| Week 12 | -2.5 ± 2.5 |
| Week 24 | -2.5 ± 2.7 |
| Week 52 | -2.0 ± 2.7 |
Mean change (LOCF) from baseline in UPDRS Part 1 sum score. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -0.33 ± 1.07 |
| Week 24 | -0.25 ± 1.17 |
| Week 52 | -0.15 ± 1.29 |
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -1.9 ± 2.8 |
| Week 24 | -1.7 ± 3.0 |
| Week 52 | -1.3 ± 3.7 |
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -3.7 ± 4.3 |
| Week 24 | -3.8 ± 4.8 |
| Week 52 | -2.5 ± 5.5 |
Mean change (LOCF) from baseline in UPDRS Part 4 sum score. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -0.24 ± 1.29 |
| Week 24 | -0.28 ± 1.32 |
| Week 52 | -0.13 ± 1.42 |
Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score. A decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -11.4 ± 9.7 |
| Week 24 | -11.1 ± 10.5 |
| Week 52 | -9.7 ± 12.1 |
Change (LOCF) from baseline in the Modified Hoehn \& Yahr Severity of Illness. The Modified Hoehn \& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided. The data at week 52 is shown.
| Percentage of participants | SPM 962 |
|---|---|
| Increased | 7.3 |
| Not changed | 62.5 |
| Decreased | 30.2 |
The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown.
| Percentage of Participants | SPM 962 |
|---|---|
| Intellectual impairment | 2.8 |
| Thought disorder | 9.5 |
| Depression | 5.0 |
| Motivation/Initiative | 4.4 |
The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown.
| Percentage of Participants | SPM 962 |
|---|---|
| Speech | 4.7 |
| Salivation | 11.0 |
| Swallowing | 6.0 |
| Handwriting | 7.6 |
| Cutting Food and Handling Utensils | 6.9 |
| Dressing | 6.6 |
| Hygiene | 5.0 |
| Turning in Bed / Adjusting Bed Clothes | 7.9 |
| Falling - Unrelated to Freezing | 8.2 |
| Freezing When Walking | 6.6 |
| Walking | 8.5 |
| Tremor | 4.4 |
| Sensory Complaints Related to Parkinsonism | 3.5 |
The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown.
| Percentage of Participants | SPM 962 |
|---|---|
| Speech | 5.8 |
| Salivation | 10.5 |
| Swallowing | 6.3 |
| Handwriting | 11.6 |
| Cutting Food and Handling Utensils | 11.6 |
| Dressing | 9.5 |
| Hygiene | 11.6 |
| Turning in Bed / Adjusting Bed Clothes | 10.5 |
| Falling - Unrelated to Freezing | 9.5 |
| Freezing When Walking | 17.9 |
| Walking | 13.2 |
| Tremor | 4.2 |
| Sensory Complaints Related to Parkinsonism | 5.8 |
The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown.
| Percentage of Participants | SPM 962 |
|---|---|
| Speech | 6.7 |
| Salivation | 13.7 |
| Swallowing | 7.6 |
| Handwriting | 12.1 |
| Cutting Food and Handling Utensils | 11.1 |
| Dressing | 9.2 |
| Hygiene | 10.2 |
| Turning in Bed / Adjusting Bed Clothes | 10.5 |
| Falling - Unrelated to Freezing | 9.9 |
| Freezing When Walking | 14.6 |
| Walking | 12.7 |
| Tremor | 5.7 |
| Sensory Complaints Related to Parkinsonism | 5.7 |
Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state). A decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -10.9 ± 9.2 |
| Week 24 | -10.5 ± 9.9 |
| Week 52 | -9.4 ± 11.4 |
The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown.
| Percentage of Participants | SPM 962 |
|---|---|
| Speech | 6.3 |
| Facial Expression | 5.4 |
| Tremor at Rest (Face, lips, chin) | 0.6 |
| Tremor at Rest (Left hand) | 1.6 |
| Tremor at Rest (Right hand) | 1.6 |
| Tremor at Rest (Left foot) | 2.2 |
| Tremor at Rest (Right foot) | 1.6 |
| Action or Postural Tremor of Hands (Left hand) | 5.4 |
| Action or Postural Tremor of Hands (Right hand) | 6.6 |
| Rigidity (Neck) | 5.0 |
| Rigidity (Left upper extremity) | 2.8 |
| Rigidity (Right upper extremity) | 2.8 |
| Rigidity (Left lower extremity) | 5.0 |
| Rigidity (Right lower extremity) | 4.1 |
| Finger Taps (Left) | 5.1 |
| Finger Taps (Right) | 5.7 |
| Hand Movements (Left) | 7.6 |
| Hand Movements (Right) | 6.6 |
| Rapid Alternating Movements of Hands (Left) | 7.3 |
| Rapid Alternating Movements of Hands (Right) | 6.9 |
| Leg Agility (Left) | 6.6 |
| Leg Agility (Right) | 7.3 |
| Arising From Chair | 9.6 |
| Posture Erect | 11.4 |
| Gait | 9.6 |
| Postural Stability | 8.9 |
| Body Bradykinesia / Hypokinesia | 7.0 |
The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown.
| Percentage of Participants | SPM 962 |
|---|---|
| Duration | 15.1 |
| Disability | 5.7 |
| Painful Dyskinesias | 0.6 |
| Presence of Early Morning Dystonia | 2.5 |
| Are "off" periods predictable? | 3.2 |
| Are "off" periods unpredictable? | 1.6 |
| Do "off" periods come on suddenly? | 1.3 |
| Proportion of "off" in waking day | 5.7 |
| Patients with anorexia, nausea, or vomiting | 5.0 |
| Patients with any sleep disturbances | 10.7 |
| Patient with symptomatic orthostasis | 1.9 |
Collected over 54 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPM 962 | — | 34/321 (10.6%) | 290/321 (90.3%) |
| Event | SPM 962 |
|---|---|
| Gastric Ulcer BleedingGastrointestinal disorders | 3/321 |
| PneumoniaInfections and infestations | 2/321 |
| Haematoma SubduralInjury, poisoning and procedural complications | 2/321 |
| Depressed Level Of ConsciousnessNervous system disorders | 2/321 |
| Colonic PolypGastrointestinal disorders | 1/321 |
| HaemorrhoidsGastrointestinal disorders | 1/321 |
| Hernia InguinalGastrointestinal disorders | 1/321 |
| Sudden DeathGeneral disorders | 1/321 |
| CholecystitisHepatobiliary disorders | 1/321 |
| Herpes ZosterInfections and infestations | 1/321 |
| Event | SPM 962 |
|---|---|
| Application Site ReactionGeneral disorders | 198/321 |
| NasopharyngitisInfections and infestations | 76/321 |
| DyskinesiaNervous system disorders | 50/321 |
| Hallucination VisualPsychiatric disorders | 34/321 |
| NauseaGastrointestinal disorders | 31/321 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 26/321 |
| ContusionInjury, poisoning and procedural complications | 24/321 |
| SomnolencePsychiatric disorders | 21/321 |
| Dental CariesGastrointestinal disorders | 20/321 |
| Back PainMusculoskeletal and connective tissue disorders | 20/321 |
| Age, Continuous(years) | SPM 962 |
|---|---|
| Mean | 65.9 ± 8.4 |
| Age, Categorical(Participants) | SPM 962 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 115 |
| >=65 years | 206 |
| Sex: Female, Male(Participants) | SPM 962 |
|---|---|
| Female | 185 |
| Male | 136 |
| Region of Enrollment(participants) | SPM 962 |
|---|---|
| Japan | 321 |
The record gives a start of Oct 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →